Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V D Schmith

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Clinical Pharmacokinetics|February 16, 1999
Clinical pharmacokinetics of cisatracurium besilateD F Kisor, V D Schmith
Clinical Pharmacology and Therapeutics|May 20, 2008
Effects of inflammation on pharmacokinetics/pharmacodynamics: increasing recognition of its contribution to variability in responseV D Schmith, J F Foss
Clinical Pharmacology and Therapeutics|February 12, 2010
Inflammation: planning for a source of pharmacokinetic/pharmacodynamic variability in translational studiesV D Schmith, J F Foss
Prostaglandins|November 1, 1995
Intravenous epoprostenol sodium does not increase hepatic microsomal enzyme activity in ratsL D Carlton, V D Schmith, K L Brouwer
Clinical Pharmacokinetics|February 1, 1991
Pharmacodynamic modelling. Application to new drug developmentP D Kroboth, V D Schmith, R B Smith
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
Pharmacometrics: Focus on the PatientT Pene Dumitrescu, M J Fossler, V D Schmith
Clinical Pharmacology and Therapeutics|July 27, 2007
Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trialsJ F Foss, D M Fisher, V D Schmith
Pharmaceutical Research|January 1, 1997
Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracuriumV D Schmith, J Fiedler-Kelly, L Phillips, et al.
Clinical Pharmacology and Therapeutics|May 1, 1992
Alprazolam in end-stage renal disease. II. PharmacodynamicsV D Schmith, B Piraino, R B Smith, et al.
Clinical Pharmacology and Therapeutics|October 15, 2010
Probabilistic risk analysis: improving early drug development decision makingP N Mudd, H Groenendaal, M A Bush, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Clinical Pharmacokinetics|February 16, 1999
Clinical pharmacokinetics of cisatracurium besilateD F Kisor, V D Schmith
Clinical Pharmacology and Therapeutics|May 20, 2008
Effects of inflammation on pharmacokinetics/pharmacodynamics: increasing recognition of its contribution to variability in responseV D Schmith, J F Foss
Clinical Pharmacology and Therapeutics|February 12, 2010
Inflammation: planning for a source of pharmacokinetic/pharmacodynamic variability in translational studiesV D Schmith, J F Foss
Prostaglandins|November 1, 1995
Intravenous epoprostenol sodium does not increase hepatic microsomal enzyme activity in ratsL D Carlton, V D Schmith, K L Brouwer
Clinical Pharmacokinetics|February 1, 1991
Pharmacodynamic modelling. Application to new drug developmentP D Kroboth, V D Schmith, R B Smith
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
Pharmacometrics: Focus on the PatientT Pene Dumitrescu, M J Fossler, V D Schmith
Clinical Pharmacology and Therapeutics|July 27, 2007
Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trialsJ F Foss, D M Fisher, V D Schmith
Pharmaceutical Research|January 1, 1997
Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracuriumV D Schmith, J Fiedler-Kelly, L Phillips, et al.
Clinical Pharmacology and Therapeutics|May 1, 1992
Alprazolam in end-stage renal disease. II. PharmacodynamicsV D Schmith, B Piraino, R B Smith, et al.
Clinical Pharmacology and Therapeutics|October 15, 2010
Probabilistic risk analysis: improving early drug development decision makingP N Mudd, H Groenendaal, M A Bush, et al.
Pageof 3